tetrasilver tetroxide: cure for AIDS?

[Guest guest]

S

Wed, 23 Aug 2006 19:31:31 -0000

tetrasilver tetroxide: cure for AIDS?

 

 

It seems very strange the patent applaction

for the hiv cure using silver tet was abandoned so far into research

after seemingly great results . Somthing is not right here .

 

 

 

 

patent #5676977

 

Here is the actual patent.

 

 

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1 & Sect2=HITOFF & d=PALL & p=1 & u=/\

netahtml/srchnum.htm & r=1 & f=G & l=50 & s1=5676977.WKU. & OS=PN/5676977 & RS=PN/5676977

 

United States Patent 5,676,977

Antelman October 14, 1997

Method of curing AIDS with tetrasilver tetroxide molecular crystal devices

 

Abstract

 

The diamagnetic semiconducting molecular crystal tetrasilver tetroxide

(Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus,

destroying AIDS synergistic pathogens and immunity suppressing

moieties (ISM) in humans. A single intravenous injection of the

devices is all that is required for efficacy at levels of about 40 PPM

of human blood. The device molecular crystal contains two mono and two

trivalent silver ions capable of " firing " electrons capable of

electrocuting the AIDS virus, pathogens and ISM. When administered

into the bloodstream, the device electrons will be triggered by

pathogens, a proliferating virus and ISM, and when fired will

simultaneously trigger a redox chelation mechanism resulting in

divalent silver moieties which chelate and bind active sites of the

entities destroying them. The devices are completely non-toxic.

However, they put stress on the liver causing hepatomegaly, but there

is no loss of liver function.

Inventors: Antelman; Marvin S. (Rehovot, IL)

Assignee: Antelman Technologies Ltd. (Providence, RI)

Appl. No.: 658955

Filed: May 31, 1996

 

Current U.S. Class: 424/618; 514/495

Intern'l Class: A61K 033/38

Field of Search: 424/618 514/495

References Cited [Referenced By]

U.S. Patent Documents

4415565 Nov., 1983 Wysor 424/618.

4915955 Apr., 1990 Gomori 424/616.

4952411 Aug., 1990 Fox, Jr. et al. 424/618.

5073382 Dec., 1991 Antelman 424/604.

5078902 Jan., 1992 Antelman 424/618.

5089275 Feb., 1992 Antelman 424/602.

5211855 May., 1993 Antelman 424/618.

5223149 Jun., 1993 Antelman 424/618.

5336499 Aug., 1994 Antelman 424/405.

5571520 Nov., 1996 Antelman 424/618.

 

 

Other References

 

" Is The AIDS Virus A Science Fiction? " by Peter H. Duesberg and Bryan

J. Ellison, Policy Review, Summer 1990, pp. 40-51.

 

Primary Examiner: Hulina; Amy

Attorney, Agent or Firm: Salter & Michaelson

Parent Case Text

 

 

This application is a continuation-in-part of patent application Ser.

No. 08/310,859 filed Sep. 22, 1994, now abandoned.

Claims

 

 

What is claimed is:

 

1. A method of treating AIDS-afflicted humans comprising injecting a

multitude of tetrasilver tetroxide molecular crystals into the

bloodstream of the human subject.

 

2. A method for increasing white blood cell counts in AIDS-afflicted

humans comprising injecting a multitude of tetrasilver tetroxide

molecular crystals into the bloodstream of the human subject.

 

3. Methods of treating AIDS-affilicted humans according to claims 1-2

where the concentration of said molecular crystals is approximately 40

PPM of the total blood weight of the human subject.

Description

 

 

BACKGROUND OF THE INVENTION

 

The present invention relates to the employment of molecular crystals

as anti-AIDS devices, but more particularly to the molecular crystal

semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which has two

monovalent and two trivalent silver ions per molecule, and which

through this structural configuration enables intermolecular electron

transfer capable of killing viruses and binding them to the resulting

silver entity so that a single intravenous injection will completely

obliterate acquired immune deficiency syndrome (AIDS) in humans.

Furthermore, said devices are capable of killing pathogens and purging

the bloodstream of immune suppressing moieties (ISM) whether or not

created by the AIDS virus (HIV); so as to restore the immune system.

 

The present invention is based on concepts previously elucidated in

applicant's U.S. Pat. No. 5,336,499 which discloses the destruction

and inhibition of bacteria, algae and the AIDS virus in nutrient life

supporting systems by using said silver oxide devices. Example 3 of

said patent discloses that 18 PPM of said crystal devices could

totally suppress the AIDS virus (page 6, line 5). Subsequent to the

filing of the aforementioned patent, further testing revealed complete

100% destruction of the AIDS virus in vitro at 20 PPM, and the fact

that said devices were harmless when ingested and inhaled, being

non-toxic.

 

Encouraged by these evaluations and successes, applicant obtained

permission to evaluate the crystals in vitro against murine acquired

immune deficiency syndrome (MAIDS). Only one facility in the State of

Israel is licensed for these evaluations, namely, the Kaplan Hospital

in Rehovot, Israel, which is affiliated with the Hebrew

University-Hadassah Medical School where said evaluations were done.

 

The initial evaluations entailed experimenting with various silver

moieties cited in applicant's aforementioned patent, concentrations,

non-reactive buffers and modes of administration. After about 18

months of judicious efforts and initial failures, success was finally

achieved in destroying the MAIDS virus in C57BL mice with a single

intravenous injection. The results of this test program comprise

Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the

inventor was able to test the efficacy of said devices on two select

etiological groups of terminal AIDS patients in a clinic in

Tegucigalpa, Honduras, Central America.

 

The AIDS patients comprised the etiological subgroups, Candidiasis and

Wasting Syndrome. Current indicator diseases for diagnosing AIDS which

have been expanded by the CDC, fall into the following five major

categories with the approximate percent distribution among AIDS patients:

 

____

1. P. carinii pneumonia

51%

2. Wasting syndrome

19%

3. Candidiasis 13%

4. Kaposi's sarcoma

11%

5. Dementia 6%

____

 

 

 

This invention concerns itself with the treatment and cure of

candidiasis and wasting syndrome AIDS patients with Tetrasil*. These

two groups account for approximately one third of AIDS cases.

 

*Trademark of Holipharm Corporation (of Israel) for Ag.sub.4 O.sub.4

 

Stedman's Medical Dictionary (Williams & Wilken's 26th Ed., 1995)

defines wasting syndrome " as a condition of 10% weight loss in

conjunction with diarrhea or fever . . . Associated with AIDS (p. 1744). "

 

OBJECTS OF THE INVENTION

 

The main object of the invention is to provide for a molecular scale

device of a single tetrasilver tetroxide crystalline molecule capable

of restoring the immunity of AIDS afflicted humans of the two AIDS

etiological subgroups, candidiasis and wasting syndrome.

 

Another object of the invention is to provide for immunity restoration

in said AIDS afflicted humans through a single injection.

 

Another object of this invention is to destroy ISM in humans

manifesting AIDS diseases of said AIDS etiological subgroups

irrespective as to whether said ISM was HIV induced, since it is known

that humans may manifest AIDS and still be HIV negative, and thus

restore the immune system in said humans.

 

Another object of this invention is to destroy the AIDS virus when

present in the systems of said AIDS afflicted humans.

 

SUMMARY OF THE INVENTION

 

This invention relates to a molecular scale device not only capable of

destroying the AIDS virus, but of purging the human bloodstream of

pathogens and restoring immunity to AIDS patients of the candidiasis

and wasting syndrome categories. Said molecular device consists of a

single crystal of tetrasilver tetroxide (Ag.sub.4 O.sub.4). The

crystal lattice of this molecule has a unique structure since it is a

diamagnetic semiconducting crystal containing two mono and two

trivalent silver ions, which in effect are capable of " firing "

electrons under certain conditions which will destroy AIDS viruses,

other pathogens and immune suppressing moieties (ISM), not only

through the electrocution mode, but also by a binding process which

occurs simultaneously with electron firing, namely, binding and

chelation of divalent silver, i.e., the resulting product of the

electron transfer redox that occur when the monovalent silver ions are

oxidized and the trivalent ions are reduced in the crystal. The

binding/chelation effect occurs at active sites of the AIDS virus,

pathogens and ISM. Because of the extremely minute size of a single

molecule of this crystal, several million of these devices may be

employed in concert to destroy a virus colony to purge a life support

system of ISM and pathogens with the consumption of only parts per

trillion of the crystal devices. Thus an optimum of 40 PPM of the

devices by weight of human blood was found to be sufficient to

completely obliterate AIDS. This concentration is slightly over double

of the optimum concentration recommended in applicant's aforementioned

U.S. patent for the destruction of the human AIDS virus in vitro.

Other details concerning the structure of the crystal and its

mechanism against pathogens, the AIDS virus and ISM would analogously

hold here, and have already been further elucidated in said patent.

 

The actual destruction of pathogens, ISM and the AIDS virus is

effectuated by injection of a suspension of these devices in distilled

or deionized water with a non-reacting electrolyte directly, i.e.

intravenously, into the bloodstream. A single injection is all that is

required under these conditions. Accordingly, humans injected in this

manner, upon being inspected after three weeks or more had elapsed and

compared with similar humans that had been given placebos, were

completely cured of AIDS. The control group still manifested AIDS.

Accordingly, the tetrasilver tetroxide device performed in concert

with and in full conformity with the ultimate objects of this

invention. Furthermore, three out of four wasting syndrome terminal

patients and four out of the five candidiasis terminal patients were

still alive in 1995 after a year and a half had elapsed from their

initial injection. By that time all the AIDS patients had been

released from the clinic and allowed to return home.

 

Other objects and features of the present invention shall become

apparent to those skilled in the art when the present invention is

considered in view of the accompanying examples. It should, of course,

be recognized that the accompanying examples illustrate preferred

embodiments of the present invention and are not intended as a means

of defining the limits and scope of the present invention.

 

EXAMPLE 1

 

Five patients afflicted with AIDS of the candidiasis etiological

category were segregated for Tetrasil treatment. The rationale for

selecting them was based on facts presented in an article by Peter H.

Duesberg and Brian J. Ellison entitled " Is The AIDS Virus A Science

Fiction? " (Policy Review, Summer 1990 pp. 40-51). Only the factual

presentations of the article were utilized and the hypothesis of the

authors was ignored. The facts presented in the article related to the

method of selecting AIDS patients based on the five aforementioned

etiological subgroups targeted by the CDC, and the evidence presented,

that there is AIDS without HIV as well as with it so that an

anti-viral agent in most instances will not necessarily restore the

immunity system.

 

Evaluations with Tetrasil were conducted on AIDS patients at Lucha

Contra el Sida, Comayaguela, Honduras. The patients two weeks prior to

inoculation were removed from their AZT, AIDS therapy. Tetrasil was

administered at approximately 40 PPM of blood volume per patient as a

suspension in a proprietary buffer solution (pH=6.5), supplied by

Holipharm Corporation.

 

The results of evaluations with candidiasis are tabulated in Table I

under its disease category. All patients evaluated were terminal.

Some, however, were in moderate (m) condition and others in poor (p)

as designated in the Table. The I and F designations refer to initial

and final values as shown. WBC indicates white cell blood count. The H

column, following CD 8, indicates whether hepatomegaly occurred. This

was an unfortunate consequence of the treatment which resulted in

enlarged livers in all patients except the second one. Despite

hepatomegaly, there was no interference with liver function.

 

The onset of hepatomegaly was not spontaneous and varied from patient

to patient, being in the range of 4-16 days.

 

It should also be noted that shortly after injection of Tetrasil there

were indications of fever (symbolized by T in the Ag.sub.4 O.sub.4

column), sometimes accompanied by fatigue (F). The body temperature

was invariably 38.5.degree. C. (101.3.degree. F.). This was indicative

of restoration of the immune response of the body, since normally the

body will destroy pathogens when the immune system is functional by

raising the temperature. The patient who died; first responded

favorably to Diflucan, which previously gave no response. He was cured

of his candidiasis, but unfortunately succumbed to his previous body

damage. All the other candidiasis syndrome people who previously did

not respond to the indicated medications subsequently responded after

the Tetrasil treatment. Further evidence of the recovery of the AIDS

patients manifested itself 30 days after the initial injection when

white blood cell counts were taken. They are shown in Table I under

the WBC column, which gives the initial and final WBC. All candidiasis

patients showed a dramatic increase in their white blood cell counts,

indicative of the restoration of their immunity systems.

 

EXAMPLE 2

 

The above protocol of Example 1 was repeated with AIDS patients

exhibiting wasting syndrome. The results of their treatment are

tabulated in Table I under the disease category of said syndrome. It

should be noted that two of the four wasting syndrome patients showed

improved white blood counts. The female patient, whose condition

improved from poor and terminal to be among the living, showed a

decrease in the WBC. However, she showed an increase in body

temperature which was indicative of immune response. The test results

indicate that one cannot rely on a single factor to indicate the

demise of AIDS. The usual HIV marker CD 4 initial and final are

irrelevant. ISM suppression appears to be more critical than the

destruction of HIV. AIDS was suppressed, any permanent damage that had

been done to the patients in the course of their succumbing to AIDS

was not obviously cured or corrected by said crystal device treatment,

rather said injury persisted and the patient was improved with respect

to AIDS but still suffered from said permanent injury or impairment

previously inflicted.

 

TABLE I

________________________

Response of AIDS Patients to Single 40 PPM Ag.sub.4 O.sub.4 Inoculation

Date Weight

DISEASE

PATIENT Inoc.

WBC CD 4 DEATH

Lbs.

Group Sex

Age

Medictn

1994

I F I F CD 8

H 1944

I F Ag.sub.4 O.sub.4

________________________

Candidiasis

M p

28 Diflucan

5/5

1,200

4,200

41

-- 221

+ 6/11

82 76

T

F m

33 " 5/5

6,000

6,700

554

872

394

- 98 98

T

F m

33 Ketaconzl

5/27

2,600

3,850

248

181

951

+ 123 123

T

M p

62 " 6/2

3,300

3,700

89

237

59

+ 105 92

F

F m

31 Pentamidn

6/2

2,400

3,050

9 181

65

+ 121 118

Pain

Wasting

M m

27 5/27

3,600

4,600

39

14

709

+ 119 120

T

Syndrome

M m

28 5/27

2,750

-- 10

-- 60

+ 7/19

121 119

T, F

F p

43 5/27

3,600

2,700

68

246

248

+ 101 98

T, F

M m

19 5/10

3,850

5,400

137

36

48

+ 103 106

T, F

________________________

 

 

 

As this invention may be embodied in several forms without departing

from the spirit or essential characteristics thereof, the present

embodiments are therefore illustrative and not restrictive, since the

scope of the invention is defined by the appended claims rather than

by the description preceding them, and all changes that fall within

the metes and bounds of the claims or that form their functional as

well as conjointly cooperative equivalents, are therefore intended to

be embraced by these claims.

 

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1 & Sect2=HITOFF & d=PALL & p=1 & u=/\

netahtml/srchnum.htm & r=1 & f=G & l=50 & s1=5676977.WKU. & OS=PN/5676977 & RS=PN/5676977